Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 112, Issue -, Pages 347-366Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2016.01.057
Keywords
Drug discovery; EphB4; In silico; Kinase; Potency; Selectivity
Categories
Funding
- Swiss National Science Foundation [315230_149897]
- Swiss Cancer League (Krebsliga) [KFS-3098]
- Forschungskredit of the University of Zurich
- Swiss National Science Foundation (SNF) [315230_149897] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Several selective and potent EphB4 inhibitors have been discovered, optimized and biophysically characterized by our groups over the past years. On the outset of these discoveries high throughput docking techniques were applied. Herein, we review the optimization campaigns started from three of these hits (Xan-A1, Pyr-A1 and Qui-A1) with emphasis on their in depth in vitro and in vivo characterization, together with previously unpublished angiogenesis and fluorescence based assays. (C) 2016 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available